You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunoglobulin G

Showing 26 - 50 of 5,980
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Guangzhou (RC18 160mg, RC18 240mg)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • RC18 160mg
  • RC18 240mg
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital,Sun Yat-Sen University
Jan 7, 2022

Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma

Not yet recruiting
  • Advanced Dedifferentiated Liposarcoma
  • +5 more
  • (no location specified)
Jan 11, 2023

Detecting IgG4-related Sclerosing Cholangitis

Completed
  • IgG4-related Sclerosing Cholangitis
  • IgG4-related Disease
    • Rochester, Minnesota
    • +1 more
    Jan 3, 2022

    HFRS (Hemorrhagic Fever With Renal Syndrome) Trial in China (IVIG 20g/d, IVIG 10g/d)

    Recruiting
    • HFRS (Hemorrhagic Fever With Renal Syndrome)
    • IVIG 20g/d
    • IVIG 10g/d
    • Guangshui, Hu Bei Province, China
    • +8 more
    Aug 22, 2023

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Jan 24, 2023

    Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial

    Active, not recruiting
    Has Results
    • Hormone-Resistant Prostate Cancer
    • +6 more
    • Pembrolizumab
    • pTVG-HP Plasmid DNA Vaccine
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Nov 8, 2022

    Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

    Recruiting
    • Biochemically Recurrent Prostate Carcinoma
    • Prostate Adenocarcinoma
    • Durvalumab
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 26, 2023

    Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Subcutaneous Immunoglobulin in Primary and Secondary

    Not yet recruiting
    • Primary Immune Deficiency Disorder
    • Secondary Immune Deficiency
    • Edmonton, Alberta, Canada
      University of Alberta
    Jun 14, 2022

    Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

    Recruiting
    • Advanced Clear Cell Renal Cell Carcinoma
    • +3 more
    • Aldesleukin
    • Pembrolizumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 5, 2022

    Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in Rochester (Durvalumab, Radiation Therapy)

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • Stage III Lung Cancer AJCC v8
    • Durvalumab
    • Radiation Therapy
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Endometrial Serous Adenocarcinoma
    • Biospecimen Collection
    • +4 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    May 12, 2023

    Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small

    Recruiting
    • Platinum-Resistant Lung Small Cell Carcinoma
    • +3 more
    • Durvalumab
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 5, 2023

    Primary Sjögren's Syndrome Trial in Yantai (Placebo, RC18 240 mg, RC18 160 mg)

    Completed
    • Primary Sjögren's Syndrome
    • Placebo
    • +2 more
    • Yantai, Shandong, China
      Remegen,Ltd.
    Jan 7, 2022

    Neuromyelitis Optica Spectrum Disorders Trial in Beijing (Placebo, RC18 160 mg)

    Recruiting
    • Neuromyelitis Optica Spectrum Disorders
    • Placebo
    • RC18 160 mg
    • Beijing, Beijing, China
      Beijing Hospital
    Jan 9, 2022

    Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Apalutamide, Biopsy, Biospecimen Collection)

    Not yet recruiting
    • Castration-Resistant Prostate Carcinoma
    • Prostate Adenocarcinoma
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jul 20, 2023

    Autoimmune Diseases Trial in Beijing (Drug free, IS monotherapy and GC combined with IS)

    Recruiting
    • Autoimmune Diseases
    • Drug free, IS monotherapy and GC combined with IS
    • Beijing, Beijing, China
      Beijing Friendship Hospital
    Jan 21, 2022

    Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Tumor Trial in United States (drug, other, biological)

    Recruiting
    • Hematologic and Lymphocytic Disorder
    • Hematopoietic and Lymphoid Cell Neoplasm
    • Placebo Administration
    • +3 more
    • Duarte, California
    • +3 more
    Dec 14, 2022

    Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,

    Completed
    • Metastatic Carcinoma in the Liver
    • +4 more
    • Durvalumab
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 30, 2023

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

    Recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • +3 more
    • Durvalumab
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 10, 2022

    Castration-Resistant Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Prostate Adenocarcinoma Trial in Houston

    Completed
    Has Results
    • Castration-Resistant Prostate Carcinoma
    • +5 more
    • Durvalumab
    • Tremelimumab
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 9, 2022

    Systemic Myasthenia Gravis Trial in Beijing (RC18 160mg, RC18 240 mg)

    Active, not recruiting
    • Systemic Myasthenia Gravis
    • RC18 160mg
    • RC18 240 mg
    • Beijing, Beijing, China
      Beijing Tiantan Hospital,Capital Medical University
    Jan 9, 2022

    Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

    Active, not recruiting
    • Recurrent Brain Neoplasm
    • Bevacizumab
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome Trial in Duarte (procedure,

    Active, not recruiting
    • Folliculotropic Mycosis Fungoides
    • +7 more
    • Extracorporeal Photopheresis
    • +3 more
    • Duarte, California
      City of Hope Medical Center
    Dec 8, 2022